OBJECTIVE: There is longstanding experimental and clinical evidence that supports the idea that replacement of dopaminergic (DAergic) neurons can ameliorate functional disabilities of Parkinson's disease (PD). The purpose of the present study is to examine the efficacy of transplantation of rat bone marrow stromal cell (BMSCs)-derived tyrosine hydroxylase-positive (TH(+)) cells induced by deprenyl into 6-hydroxydopamine (6-OHDA)-lesioned rat models, using behavioral tests and immunohistochemical evaluations. MATERIALS AND METHODS: In this experimental study, undifferentiated BrdU-labeled BMSCs were incubated in serum-free medium that contained 10(-8) M deprenyl for 24 hours. Afterwards, BMSCs were cultured for 48 hours in α-minimal essential medium (α-MEM) supplemented with 10% FBS, then differentiated into TH(+) neurons. We randomly divided 24 hemiparkinsonian rats as follows: group 1 (control) received only medium, while groups 2 and 3 were injected with 2×10(5) BMSCs and deprenyl-treated cells in 4 µl medium. Injections were made into the injured strata of the rats. Rotational behavior in response to apomorphine was tested before transplantation and at 2, 4, and 6 weeks post-graft. Animals were then sacrificed, and the brains were extracted for immunohistochemical and electron microscopic studies. RESULTS: Apomorphine-induced rotation analysis indicated that animals with grafted cells in groups 2 and 3 exhibited significantly less rotational behavior than those in the control group at 2, 4, and 6 weeks after transplantation. Immunohistochemical analysis demonstrated that BrdU-labeled cells expressed specific neuronal markers, such as NF 200 and TH, at the implantation site. The presence of TH(+) cells in conjunction with the reduction in rotation might show the capacity of grafted cells to release dopamine. Ultrastructural analysis revealed the presence of immature neurons and astrocyte-like cells at the graft site. CONCLUSION: TH(+) neurons induced by deprenyl can be considered as a cell source for PD autograft therapy.
OBJECTIVE: There is longstanding experimental and clinical evidence that supports the idea that replacement of dopaminergic (DAergic) neurons can ameliorate functional disabilities of Parkinson's disease (PD). The purpose of the present study is to examine the efficacy of transplantation of rat bone marrow stromal cell (BMSCs)-derived tyrosine hydroxylase-positive (TH(+)) cells induced by deprenyl into 6-hydroxydopamine (6-OHDA)-lesioned rat models, using behavioral tests and immunohistochemical evaluations. MATERIALS AND METHODS: In this experimental study, undifferentiated BrdU-labeled BMSCs were incubated in serum-free medium that contained 10(-8) M deprenyl for 24 hours. Afterwards, BMSCs were cultured for 48 hours in α-minimal essential medium (α-MEM) supplemented with 10% FBS, then differentiated into TH(+) neurons. We randomly divided 24 hemiparkinsonian rats as follows: group 1 (control) received only medium, while groups 2 and 3 were injected with 2×10(5) BMSCs and deprenyl-treated cells in 4 µl medium. Injections were made into the injured strata of the rats. Rotational behavior in response to apomorphine was tested before transplantation and at 2, 4, and 6 weeks post-graft. Animals were then sacrificed, and the brains were extracted for immunohistochemical and electron microscopic studies. RESULTS:Apomorphine-induced rotation analysis indicated that animals with grafted cells in groups 2 and 3 exhibited significantly less rotational behavior than those in the control group at 2, 4, and 6 weeks after transplantation. Immunohistochemical analysis demonstrated that BrdU-labeled cells expressed specific neuronal markers, such as NF 200 and TH, at the implantation site. The presence of TH(+) cells in conjunction with the reduction in rotation might show the capacity of grafted cells to release dopamine. Ultrastructural analysis revealed the presence of immature neurons and astrocyte-like cells at the graft site. CONCLUSION: TH(+) neurons induced by deprenyl can be considered as a cell source for PD autograft therapy.
A number of psychiatric and movement disorders
in humans, such as Parkinson’s disease
(PD), are caused by the degeneration or dysfunction
of dopaminergic (DAergic) neurons in the
substantia nigra pars compacta with a subsequent
reduction in striatal dopamine, which leads to
a disruption in the normal function of the basal
ganglia (1, 2). This highlights the importance of
DAergic neurons for maintenance of health and
explains why these cell types are the subject of
extensive investigation. Clinical experiments using
cell transplantation as a therapy for PD have
been conducted since 1980.The replacement of degenerated neurons with
effectively functional exogenous potent stem
cells is a more promising technique for tissue
repair and regeneration in cases of PD (2). Fetal
DAergic cells originate in the ventral mesencephalic
tissue that has been obtained from
fetuses, and have the potential to improve motor
function in animal models of PD. However,
technical difficulties in obtaining sufficient graft
tissues, ethical considerations, and rejection of
cells are limitations for the application of this
therapy (3-5).Over the last 20 years scientists have been
searching for other reliable sources of midbrain
DA neurons, of which stem cells appear to be
promising candidates. There are three sources of
stem cells that are currently being researched:
embryonic stem cells (ESCs), neural stem cells
(NSCs), and mesenchymal stem cells (MSCs).
NSCs are isolated from embryonic or adult
brains; they can only generate nervous system
cell lines, and have less potential than ES cells
(6, 7).The ethical debate on using aborted embryo
cells and the risk of tumor formation have limited
the use of ESCs. Bone-marrow mesenchymal
stem cells (BMSCs) can represent an alternative
source of stem cells for cell replacement therapies
(8-11). They are easily isolated from hematopoietic
stem cells, avoid ethical problems,
and can be used for autologous transplantation
(12). Recently, many protocols that use in vitro
differentiation of BMSCs into DAergic neurons
have been developed (13, 14). These protocols
involve the direct administration of growth factors
and/or chemicals in cultures, or ectopic expression
of their coding sequences within cells
(15-17).Previous studies have shown that neural-like
cells can be produced in vitro from BMSCs following
induction of deprenyl (18, 19). Selegiline,
or L-deprenyl, is a monoamine oxidase-
B (MAO-B) inhibitor that slows the progression
of PD. Deprenyl is known to increase the survival
of cultured nigral DAergic neurons, protecting
them from oxidative stress. The trophic
effects of selegiline may play a significant role
in the treatment of neurodegenerative diseases
(20, 21).It has been reported that deprenyl can protect
hippocampal neurons from excitotoxic damages,
most likely by induction of NGF protein. Studies
also show that it may have the neuroprotective effects
and trophic effects of deprenyl (22, 23). In
this study, we have generated TH+ cells from rat
BMSCs by induction of deprenyl, as previously
reported, and then transplanted them into 6-hydroxydopamine
(6-OHDA)-treated rats in order to
investigate the clinical efficacy of these cells.
Materials and Methods
Animals
The experimental protocol was approved by
the Research and Ethics Committee of Damghan
University. Adult male Sprague-Dawley rats that
weighed 200-250 g were purchased from Razi
Institute, Karaj, Iran. Animals were kept under
standard laboratory conditions with a 12 hours
light/dark cycle and ad libitum food and water
throughout the experiments.
Preparation of bone marrow stromal cells and production
of tyrosine hydroxylase–positive neurons
Animals were killed and femurs were dissected
out. The marrow was extruded with
α-minimal essential medium (α-MEM). The extracted
solution was centrifuged at 150 x g for
10 minutes after which the cell pellet was resuspended
in α-MEM supplemented with 10%
FBS, penicillin (100 µM/ml, Gibco, USA), and
streptomycin (100 µM/ml; Gibco) in a 25 cm2
tissue culture flask at 37˚C and 5% CO2 accord ing to a protocol by Rismanchi et al. (24). The
culture medium was changed every 3-4 days to
remove any non-adherent cells. When the flask
reached 80% confluency (usually within two
weeks), cells were harvested by incubation in
0.25% trypsin and 0.5 mM EDTA (Merck, Germany)
at 37˚C for 3-4 minutes, after which they
were subcultured.Continuous subculturing of cells was performed
for five passages. The fifth passage of the cells
were treated with serum-free medium (25, 26) that
contained 10-8 M of deprenyl for 24 hours, then
cultured in α-MEM that contained 10% FBS for
48 hours (23, 24).
Identification of transplanted cells
NF-200, synapsin, and TH immunocytochemistry
were used to identify differentiated
cells (19). Cells were cultured on gelatinized
coverslips and fixed in 4% paraformaldehyde
for 20 minutes at 4˚C, then permeabilized in
0.1% triton X-100 for 15 minutes and blocked
in 10% normal goat serum for 15 minutes.
Cells were incubated with primary antibodies,
mouse anti-NF200 (Sigma, N5389, Germany)
and rabbit anti-TH (Chemicon, AB152, USA),
overnight at 4˚C. After three washes in 0.01
M phosphate buffered saline (PBS), the cells
were incubated with secondary antibodies at
37˚C for 30 minutes. The secondary antibodies
were HRP and FITC-conjugated anti-rabbit
for the TH marker and FITC-conjugated
anti-mouse for NF-200 (27). Expressions of
TH and Nurr1 were determined by reverse
transcription-polymerase chain reaction (RTPCR).
Total RNA was extracted using a CinnaGen
kit and 0.5 µg of total RNA was transcribed
into cDNA with a Fermentase-k1622
kit. Subsequent PCR was performed with 5 µg
of synthesized cDNA, 1×PCR buffer, 50 mM
of MgCL2, 10 mM of dNTPs, 10 pmol of forward
and reverse primers, 0.25 µl Taq DNA
polymerase enzyme, and injection water with
a terminal volume of 25 µl in thermal cycler
with 34 cycles.Table 1 lists the primers used in this study.
β2 microglobulin (β2M) was used as the housekeeping
(internal control) gene. RT-PCR was
carried out in a master cycler (Eppendorf,
Germany) using the following cycling parameters:
initial denaturation at 94˚C for 2 minutes;
followed by 34 cycles according to the
program; denaturation at 94˚C for 30 seconds;
annealing at 55˚C for 30 seconds; extension
(elongation) at 72˚C for 30 seconds; at the end
of 34 th cycle, the end stage of terminal extension
was carried out at 72˚C for 5 minutes.
The experiment was repeated three times for
each sample; all stages were controlled in the
cDNA preparation stage by deleting the RNA
sample and reverse transcriptase, and in the
RT-PCR stage by deleting Taq polymerase and
the cDNA product.
Unilateral corpus striatum 6-OHDA lesions and
transplantation
Adult male Sprague-Dawley rats (weights:
250-300 g) received stereotaxic injections of 3
µl 6-OHDA (10 µg/µl dissolved in 1% ascorbate-
saline) into their left striata via a metal
cannula attached to a 10 µl Hamilton microsyringe
at a rate of 1 µl/min. The injection site (AP
+ 1 mm, L-3 mm, V + 5 mm from the bregma)
was according to the Paxinos and Watson atlas
(29). After two weeks, lesioned animals were
selected for transplantation surgery by counting
apomorphine (0.05 mg/kg i.p.) -induced turning
behavior (28-30); only animals that showed at
least seven full turns/min against the lesioned
side were selected for transplantation surgery
(31). The rotation tests were repeated at 2, 4,
and 6 weeks after transplantation.To harvest donor cells for transplantation experiments,
BrdU labeled deprenyl-treated cells
(3) were incubated with 0.25% trypsin/0.04%
EDTA at room temperature for 5 minutes. Cell
suspension was then prepared at a concentration
of 2×105 cells in 5 µl medium. The cell viability
was ~90% just prior to grafting. The cell suspension
was injected into the injured striatum
of each rat by using a stereotaxic apparatus and
automatic microinjection pump at an injection
rate of 1 µl/min (32).Hemiparkinsonian rats were randomly divided
into three groups: i. those that received only
medium (control), ii. those transplanted with
BMSCs, and iii. those that received an injection
of deprenyl-treated cells.The primers used for reverse transcription-polymerase chain reaction analysis
Immunohistochemical study
Identification of BrdU-labeled cells was performed
via immunocytochemical staining. Six
weeks after implantation, animals were anesthetized
and transcardially perfused. Rats'
brains were postfixed with 4% paraformaldehyde,
processed for paraffin embedding, and
sectioned into 5 µm thicknesses.A series of sections were prepared for BrdU,
TH, and NF-200 immunostaining. A number of the
paraformaldehyde-fixed brains were incubated in
30% sucrose until they sank. Sections were cut on
a freezing microtome at 40 µm, and processed for
TH and BrdU immunohistochemistry.The sections were rehydrated, incubated in
50% formamide/2X standard sodium citrate
(SSC: 0.3 M NACl, 0.03 M sodium citrate) for
120 minutes at 60˚C, washed with 2X SSC for
10 minutes (both at room temperature), incubated
in 2N HCl at 37˚C for 30 minutes, rinsed
in 0.1 boric acid (pH=8.5) for 10 minutes, and
washed in PBS. The sections were then incubated
in blocking serum, followed by incubation
with mouse anti-BrdU monoclonal antibody
(Sigma, St. Louis, MO, USA, B2531) or anti-
TH antibody overnight at 4˚C, and followed by
labeling with anti-mouse IgG-peroxidase antibody
in goat (Sigma, A9917, USA) for 2 hours
at room temperature (33).For double immunostaining, some sections
were incubated with mouse anti-BrdU monoclonal
antibody and subsequently with secondary
antibody conjugated with rhodamine, while
the secondary antibody for anti-NF200 or anti-
TH antibodies was conjugated with FITC. Finally
the two images were merged.
Statistical analysis
Statistical analyses were carried out using
one-way ANOVA with Tukey’s multiple comparison.
For each parameter, the significance
level was determined using SPSS (version 16).
Data are expressed as mean ± SEM. P≤0.05 was
considered statistically significant.
Results
Characterization of transplanted cells
Cultured BMSCs with spindle-shaped morphology
and deprenyl-treated BMSCs with neural
morphological characteristics are shown in Figs 1
A and B. In addition, immunocytochemical evaluations
in figure 1 C-F show that the majority of
treated cells in the microscopic field were immunopositive
for TH, NF200, and synapsin.Before transplantation, we sought to determine
if deprenyl-treated cells that were to be
used as grafts truly included DA neurons. As
shown in figure 2, there was no mRNA expression
of TH and a weak band of Nurr1 in untreated
cells, but the mRNA expression of these
genes significantly increased in deprenyl-treated
cells compared to undifferentiated cells.The detectable level of DA released into supernatant
was 8.9 ± 0.02 ng in treated cell.Deprenyl-treated rat mesenchymal stem cells (MSCs) display neural morphology and express neuronal markers.
A. Fifth passage of cultured bone marrow MSCs (BMSCs); B cultured BMSCs following neuronal induction by
deprenyl; C, D. treated cells demonstrated immunoreactivity for tyrosine hydroxylase (TH); E. synaptophysin; and
F. NF200.RT-PCR analysis of tyrosine hydroxylase (TH) and Nurr1 expression in deprenyl-treated and untreated rat bone marrow mesenchymal
stem cells (BMSCs) . A. There was no mRNA expression of TH and a weak band of Nurr1 in untreated cells; B. mRNA expression
of these genes significantly increased in deprenyl-treated cells compared with that of undifferentiated cells; C. data were statistically
significant at *p<0.05 as compared to control using one-way ANOVA. The mRNA expression of these genes significantly increased in
deprenyl-treated cells compared with undifferentiated cells.
Apomorphine-induced rotation analysis
In figure 3 (2, 4, and 6 weeks after transplantation)
the number of apomorphine-induced rotations
significantly reduced in groups 2 and 3 compared
to the control group (p≤0.05). There was a
significant reduction of contralateral rotations to
the lesion side in group 3 between 2 and 4 weeks,
as well as between 2 and 6 weeks after transplantation,
but no significant reduction in group 2 was
observed during these two time periods.The deprenyl-treated cell grafted animals had
more rapid improvement of rotational behavior
than BMSC-grafted animals.Analysis of rotational behavior induced by apomorphine.
Apomorphine-induced circling behavior was evaluated at 2, 4,
and 6 weeks after transplantation. Rats from the grafted groups
were given BrdU-labeled bone marrow mesenchymal stem cells
(BMSCs) that were undifferentiated and BrdU-labeled deprenyl-
treated cells which were differentiated. Control animals
received intrastriatal injections of medium. No recovery of rotational
behavior was detected in control rats, whereas the grafted
rats exhibited significantly decreased rotational behavior.
Histological and immunohistochemical analysis
Tissue sections were immunostained with
anti-BrdU and anti-TH at the implantation
site six weeks after grafting. BrdU+ or TH+
cells were observed in the striatum exclusively
close to the grafted region, as illustrated in
figure 4 A-E.A. BrdU + cells at the implantation site; B. BrdU
+ transplanted cells are engrafted in the site of injury;
C, D. cryosection of implantation site shows tyrosine hydroxylase-
positive (TH +) cells; E. negative control (primary
antibody was deleted).To ensure that transplanted cells that expressed
neuronal lineage markers were of deprenyl-treated
cell-origin, some sections were double stained for
both a neuronal marker (NF200 or TH) and BrdU
(Fig 5).
Fig 5
Immunostaining of the host striatum grafted with deprenyl-treated cells six weeks after transplantation. A, B, C, D are out of
order. Please fix.) B. The tissue section was double-labeled with anti-neurofilament 200 antibody (secondary antibody conjugated with
FITC) and anti-BrdU antibody (secondary antibody conjugated with rhodamine), then the two images were merged. A. Phase contrast
photomicrograph of the field in the upper panel. D Upper panel: the tissue section was double labeled with anti-tyrosine hydroxylase
(TH) antibody (secondary antibody conjugated with FITC) and anti-BrdU antibody (secondary antibody conjugated with rhodamine),
then the two images were merged. C. Phase contrast photomicrograph of the field in the upper panel.
The majority of implanted areas were found to
also express TH marker; the majority of grafted
areas were aggregated with immunopositive cells.
Therefore, we were unable to determine the number
of TH+ cells present in the grafts.Some of cells that were immunopositive for TH
were also positive for BrdU, which demonstrated
the presence of TH+ neurons derived from the
transplanted cells had engrafted at the injury site.
Electron microscopic study
The ultramicrostructure of the corpus striatum
in figure 6 showed that in group 3 a few cells at
the implantation region showed characteristics
of immature neurons, which consisted of a large
amount of polysomes and rough endoplasmic reticuli.
Astrocyte-like cells were observed among
the neurons at the implantation region.Immunostaining of the host striatum grafted with deprenyl-treated cells six weeks after transplantation. A, B, C, D are out of
order. Please fix.) B. The tissue section was double-labeled with anti-neurofilament 200 antibody (secondary antibody conjugated with
FITC) and anti-BrdU antibody (secondary antibody conjugated with rhodamine), then the two images were merged. A. Phase contrast
photomicrograph of the field in the upper panel. D Upper panel: the tissue section was double labeled with anti-tyrosine hydroxylase
(TH) antibody (secondary antibody conjugated with FITC) and anti-BrdU antibody (secondary antibody conjugated with rhodamine),
then the two images were merged. C. Phase contrast photomicrograph of the field in the upper panel.Electron microscopic study . A. Numerous amounts of polysomes and rough endoplasmic reticuli indicated immature
neurons (arrow) at the implantation region; B. an astrocyte-like cell among the transplanted cells (shown by star).
Discussion
Cell replacement therapy for PD is dependent upon
a reliable source of purified DAergic neurons and the
identification of factors relevant to their survival (2).
The number of DAergic neurons that survive in the
graft is relevant to the in vitro methods used to purify
and quantify these cells prior to transplantation.
DAergic neurons are derived from the fetal midbrain,
embryonic, or adult stem cells. There are very low
numbers of DAergic neurons in the fetal midbrain
(depending on the dissected section), and more than
95-99% of cells are not DA neurons. Transplantation
of these unwanted cells produces serious side effects,
and in rare cases, even deathMSCs of the bone marrow are capable of differentiating
along multiple lineages including neural
cells, and have significant expansion capacity unlike
other stem cells. BMSCs are capable of migrating
to repair injured tissues (4). We have used
BMSCs due to the numerous advantages for their
clinical application. First, bone marrow is far more
accessible than NSCs and ES cells. In addition,
there are no ethical and immunological problems
associated with BMSCs because they can be obtained
from the patients, themselves. LU et al.
(16) initially noted that BMSCs express not only
mesodermal-related genes, but also endodermal
and neuroectodermal-related genes even before
neuronal induction, and therefore defined BMSCs
not as "undifferentiated" but rather as "multidifferentiated"
cells. Marrow stromal cell expression
of several neural genes, even before induction, has
been confirmed by several studies (34). Several in
vitro culturing methods have thus far been developed
to generate DAergic neurons from BMSCs.
BMSCs can be considered a suitable candidate to
undergo directed to a DAergic fate in vitro and as
a cell source for autograft therapy of PD. BMSCs
are the subject of treatment of neurodegenerative
diseases by secreting neurotrophic factors. BMSCs
could be directed to a DAergic fate by adding
neurotrophic factors in a culture medium or by ectopic
expression of their coding sequences within
the cells. However, many of these chemicals have
been reported to have mutagenic, teratogenic, or
carcinogenic properties (15-17). Esmaeili et al.
(35) has reported that deprenyl can induce ESCs
differentiation into a neuronal phenotype with immunoreactivity
to synaptophysin and TH. Ghorbanian
et al. (19) showed that induced BMSCs were
immunoreactive for NF 200, NF68, and synapsin
I and expressed BDNF, NGF, NT-3, neuroligin 1,
and PSD-95.In this study, by using a specific differentiation
protocol which was reported previously, we have
demonstrated that it is possible to isolate an approximately
pure population of DAergic neurons
from BMSCs by deprenyl induction. Before transplantation,
we examined whether the treated cells
that were to be used as a graft actually had DAergic
neurons. The results revealed that deprenyl could
induce BMSCs differentiation into neuronal phenotype
with synaptophysin, TH, NF200 immunoreactivity,
dopamine secretion, and TH and Nurr1
gene expression. Deprenyl also had a trophic-like
effect on cultured cells and stimulated their proliferation
rate.Nurr1 is involved in DAergic neuron development
and survival, while the TH gene is related
to DA synthesis (2). Analysis of semi-quantitative
RT-PCR data revealed that the expression of Nurr1
and TH mRNAs of treated cells increased significantly
compared with those of untreated cells.
Next, we examined whether deprenyl-treated cells
could survive and ameliorate some of the behavioral
deficits after transplantation.It was reported previously that rat BMSCs transplanted
to 6-OHDA-lesioned rats differentiated
into TH+ neurons. Transplanted mesenchymal cells
appear to indirectly affect brain repair. Suggested
mechanisms include production of growth factors,
cytokines, and neurotrophic factors; promotion of
the proliferation of endogenous progenitor cells;
and the generation of favorable substrate for axonal
growth or effects on the vasculature (36).Apomorphine-induced rotation analysis showed
improved rotational behavior in grafted animals
compared to lesioned animals without any grafts.
DAergic neuron transplantation caused behavioral
recovery, which showed that intrastriatal DAergic
grafts survive and establish synaptic connections
with the host striatum and secrete dopamine.Deprenyl-treated cell grafted animals showed
more rapid improvement of rotational behavior
than BMSCs-grafted animals. We observed a significant
difference of motor behavior after injection
of apomorphine, which was accompanied by
the integration of TH+ cells at the lesioned side
when compared with control (lesioned, medium injected) rats. Functional recovery required complete
neural differentiation and integration with
the host nervous system.Six weeks after transplantation, grafted cells
were immunohistochemically distinct from the
host brain by positive immunoresponse; it seemed
that donor cells were more fully integrated into the
host tissue. To ensure that cells which expressed
neuronal markers at the implantation site were of
BMSCs origin, they were double-stained for both
neuronal markers (NF-200 or TH) and BrdU. By
double staining TH and BrdU, TH-positive neurons
were identified at the implantation site, and
we observed that transplanted cells survived and
became well integrated into the host tissue.
Conclusion
DAergic neurons that were produced in our
differentiation protocol survived at the implantation
area and reduced the lesion-induced circling
behavior in a PDrat model. In addition,
the striatum is a target area for DAergic neurons,
and it may produce growth factor that increases
the survival of DAergic neurons. DAergic neurons
obtained from BMSCs in the presence of
deprenyl expressed specific markers such as
Nurr1 and TH, and released DA in vitro, were
found to improve the behavioral deficits in Parkinsonianrat models.In the future, we intend to identify factors, cells
and conditions that will enhance the survival of
deprenyl-induced TH+ neurons in vivo and in vitro.
Our goal will be to identify essential growth
factors relevant to DAergic neuron survival and
proliferation rate; factors such as GDNF and the
GDNF family members (neurturin, artemin, persephin),
which are believed to have a neurotrophic
effect on DAergic neurons.This study may create the necessary foundation
to generate consistently successful grafts in patients
diagnosed with PD.
Table 1
The primers used for reverse transcription-polymerase chain reaction analysis